US 11,723,897 B2
Fatty acids as anti-inflammatory agents
Bruce A. Freeman, Pittsburgh, PA (US); and Francisco J. Schopfer, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Oct. 14, 2020, as Appl. No. 17/70,769.
Application 17/070,769 is a continuation of application No. 16/239,425, filed on Jan. 3, 2019, granted, now 10,835,518.
Application 16/239,425 is a continuation of application No. 15/662,024, filed on Jul. 27, 2017, granted, now 10,213,417, issued on Feb. 26, 2019.
Application 15/662,024 is a continuation of application No. 14/717,954, filed on May 20, 2015, granted, now 9,750,725, issued on Sep. 5, 2017.
Application 14/717,954 is a continuation of application No. 13/387,489, granted, now 9,066,902, issued on Jun. 30, 2015, previously published as PCT/US2010/002141, filed on Aug. 2, 2010.
Claims priority of provisional application 61/213,946, filed on Jul. 31, 2009.
Prior Publication US 2021/0236469 A1, Aug. 5, 2021
Int. Cl. A61K 31/426 (2006.01); A61K 31/231 (2006.01); A61K 31/232 (2006.01); A61K 31/12 (2006.01); A61K 31/4166 (2006.01); A61K 31/4192 (2006.01); A61K 31/421 (2006.01)
CPC A61K 31/426 (2013.01) [A61K 31/12 (2013.01); A61K 31/231 (2013.01); A61K 31/232 (2013.01); A61K 31/4166 (2013.01); A61K 31/4192 (2013.01); A61K 31/421 (2013.01); Y02A 50/30 (2018.01)] 6 Claims
 
1. A pharmaceutical formulation comprising: an effective amount of a compound having a formula of:

OG Complex Work Unit Chemistry
wherein R1 is hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, (C1-C8)fluoroalkyl, (C1-C8)hydroxyalkyl, (C3-C8)cycloalkyl, (C4-C8)bicycloalkyl, (C3-C8)heterocycloalkyl, heteroaryl, aryl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C3-C8)heterocycloalkyl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl or aryl(C1-C6)alkyl; X is sulfur, oxygen, or nitrogen atom; and m is 0 to 15; and
a pharmaceutically acceptable carrier.